Clinical development of angiogenesis inhibitors to vascular endothelial growth factor and its receptors as cancer therapeutics

Current Cancer Drug Targets

Volumn 2, Issue 2, 2002, Pages 135-156

  Zhu, Zhenping ^a   Bohlen, Peter ^a   Witte, Larry ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ANGIOGENESIS INHIBITOR; IMMUNOTOXIN; RIBOZYME; SEMAXANIB; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

CANCER PATIENT; CANCER THERAPY; CONFORMATIONAL TRANSITION; DRUG EFFECT; ENDOTHELIUM CELL; GENE TARGETING; GROWTH INHIBITION; MITOGENICITY; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; REVIEW; TARGET CELL; TUMOR GROWTH;

ANGIOGENESIS INHIBITORS; ANIMALS; ENDOTHELIAL GROWTH FACTORS; HUMANS; LYMPHOKINES; NEOPLASMS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0036279804     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568009023333881     Document Type: Review

References (220)

1. What is the evidence that tumors are angiogenesis-dependent?
2. Angiogenesis in cancer, vascular, rheumatoid and other disease
3. Tumor micrometastases: The influence of angiogenesis
4. Tumor angiogenesis: Molecular pathology, therapeutic targeting, and imaging
5. Tumor angiogenesis: Past, present and the near future
6. Angiogenesis in cancer and other diseases
7. Cancer metastasis and angiogenesis: An imbalance of negative and positive regulation
8. The implications of angiogenesis for the biology and therapy of cancer metastasis
9. Regulators of angiogenesis
10. Function of fibroblast growth factors and vascular endothelial growth factors and their receptors in angiogenesis
11. Angiogenesis: Regulators and clinical applications
12. Vascular endothelial growth factor is a secreted angiogenic mitogen
13. The role of vascular endothelial growth factor in pathological angiogenesis
14. Vascular endothelial growth factor
15. Vascular permeability factor/vascular endothelial growth factor: A multifunctional angiogenic cytokine
16. VEGF: An update on biological and therapeutic aspects
17. Regulation of angiogenesis via vascular endothelial growth factor receptor
18. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
19. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
20. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice
21. A requirement for Flk1 in primitive and definitive hematopoiesis and vasculogenesis
22. Role of the Flt-1 receptor tyrosine kinase in regulating the Assembly of Vascular Endothelium
23. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant
24. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo
25. Halting angiogenesis suppresses carcinoma cell invasion
26. Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor
27. Anti-angiogenic agent: Clinical trial design and therapies in development
28. New paradigms for the treatment of cancer: The role of anti-angiogenesis agents
29. Angiogenesis inhibitors: New agents in cancer therapy
30. Antiangiogenic strategies and agents in clinical trials
31. Target molecules for anti-angiogenic therapy: From basic research to clinical trials
32. Current stutas of antiangiogenic factors
33. Tumor vasculature as targe for anticancer therapy
34. General aspects of anti-angiogenesis and cancer therapy
35. Vascular endothelial growth factor and its receptors
36. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor
37. Vascular endothelial growth factor B, a novel for endothelial cells
38. VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development
39. Vascular endothelial growth factor D (VEGF-D) is a Ligand for the tyrosine kinase VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)
40. A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain
41. Vascular endothelial growth factor (VEGF)-like protein from orf virus NZ2 binds to VEGFR2 and neuropilin-1
42. The vascular endothelial growth factor family: Identification of a fourth molecular species and characterization of alternative splicing of RNA
43. The human gene for vascular endothelial growth factor
44. The carboxy-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency
45. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms
46. Identification of vascular endothelial growth factor determinants for binding KDR and Flt-1 receptors
47. Inhibition of Vascular Endothelial Growth Factor (VEGF)-induced endothelial cell proliferation by a peptide corresponding to the exon 7-encoded domain of VEGF 165
48. VEGF 145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix
49. Purification and characterization of a naturally occurring vascular endothelial growth factor/placenta growth factor heterodimer
50. Heterodimers of placenta growth factor/vascular endothelial growth factor. Endothelial activity, tumor cell expression, and high affinity binding to Flk-1/KDR
51. Protoeolytic processing regulates receptor specificity and activity of VEGF-C
52. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice
53. VEGF and VEGF-C: Specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane
54. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases
55. Vascular endothelial growth factor-related protein: A ligand and specific activator of the tyrosine kinase receptor Flt4
56. Identification of a C-Fos-induced gene that is related to the platelet-derived growth factor/vascular endothelial growth factor family
57. Vascular endothelial growth factor (VEGF)-C synergizes with basic fibroblast growth factor and VEGF in the induction of angiogenesis in vitro and alters endothelial cell extracellular proteolytic activity
58. Homologs of vascular endothelial growth factor are encoded by the poxvirus orf virus
59. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (Flt-1) closely related to the Fms family
60. The Fms-like tyrosine kinase, a receptor for vascular endothelial growth factor
61. Identification of the KDR tyrosine kinase receptor as a receptor for vascular endothelial growth factor
62. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis
63. Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium
64. High affinity binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis
65. Vascular endothelial growth factor receptor expression during embryogenesis and tissue repair suggests a role in endothelial differentiation and blood vessel growth
66. FLT-4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines
67. The FLT4 gene encodes a transmembrane tyrosine kinase related to the vascular endothelial growth factor receptor
68. Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF 165 via its exon 7-encoded domain
69. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor
70. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice
71. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR
72. Inhibition of vascular endothelial growth factor activity by an endogenously encoded soluble receptor
73. Paracrine expression of a native soluble vascular growth factor receptor inhibits tumor growth, metastasis, and mortality rate
74. A receptor tyrosine cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit
75. Vascular endothelial growth factor: Crystal structure and functional mapping of the kinase domain receptor binding site
76. Requirements for binding and signaling of the kinase domain receptor for vascular endothelial growth factor
77. Characterization of a soluble vascular endothelial growth factor receptor-immunoglobulin chimera
78. Mapping of the sites involved in ligand association and dissociation at the extracellular domain of the kinase insert domain-containing receptor for vascular endothelial growth factor
79. Identification of the residues in the extracellular region of KDR important for the interaction with vascular endothelial growth factor and neutralizing anti-KDR antibodies
80. Crystal structure at 1.7 a resolution of VEGF in complex with domain 2 of the Flt-1 receptor
81. Mapping of the sites for ligand binding and receptor dimerization at the extracellular domain of the vascular endothelial growth factor receptor FLT-1
82. Identification of the extracellular domains of Flt-1 that mediate ligand interactions
83. Mapping the charged residues in the second immunoglobulin-like domain of the vascular endothelial growth factor/placenta growth factor receptor Flt-1 required for binding and structural stability
84. The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade
85. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor
86. The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells
87. A unique signal transduction pathway for the FLT tyrosine kinase, a receptor for vascular endothelial growth factor
88. Biological activity and phosphorylation sites of the bacterially expressed cytosolic domain of the KDR VEGF-receptor
89. Identification of vascular endothelial growth factor receptor-1 tyrosine phosphorylation sites and binding of SH2 domain-containing molecules
90. Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain SH2 domains. Association with endothelial cell proliferation
91. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt Signal transduction pathway
92. Vascular endothelial growth factor stimulates tyrosine phosphorylation and recruitment tto new focal adhesions of focal adhesion kinase and paxillin in endothelial cells
93. The 230 kDa mature form of KDR/Flk-1 (VEGF receptor-2) activates the PLC-γ pathway and partially induces mitotic signals in NIH3T3 fibroblasts
94. Receptor-selective variants of human vascular endothelial growth factor. Generation and characterization
95. Analysis of biological effects and signaling properties of Flt-1 (VEGFRI) and KDR. A reassessment using novel receptor-specific vascular endothelial growth factor mutants
96. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor Flt-1
97. The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis
98. Signaling pathways induced by vascular endothelial growth factor
99. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract
100. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer
101. Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia
102. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas
103. Vascular permeability factor gene expression in normal and neoplastic human ovaries
104. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in endometrial carcinoma
105. Strong expression of KDR, vascular permeability factor/vascular endothelial growth factor receptor in AIDS-associated Kaposi's sarcoma and cutaneous angiosarcoma
106. Vascular endothelial growth factor is a potential tumor angiogenesis factor in human glioma in vivo
107. Expression of vascular permeability factor / vascular endothelial growth factor gene in central nervous system neoplasms
108. Up-regulation of vascular endothelial growth factor and its receptors in Von Hippel-Lindau disease-associated and sporadic hemangioblastomas
109. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies
110. Tumor angiogenesis and metastasis. Correlation in invasive breast carcinoma
111. Angiogenesis in bladder cancer: Relationship between microvessel density and tumor prognosis
112. Comparison of microscopic vascularity in benign and malignant prostatic tissue
113. Prognostic and predictive value of tumor angiogenesis in ovarian carcinomas
114. Prognostic significance of the microvascular count in colorectal cancer
115. Extent of tumor vascularization correlates with prognosis and hematogenous metastasis in gastric carcinoma
116. Relation of neovascularisation to metastasis of non-small cell lung cancer
117. The significance of atypical vessels and neovascularization in cervical neoplasias
118. Angiogenesis and tumor progression of melanoma: Quantification of vascularity in melanocytic nevi and cutaneous malignant melanoma
119. Neovascularization in clinical stage a testicular germ cell tumor: Prediction of metastatic disease
120. Intratumoral microvessel density and p53 protein: Correlation with metastasis in head and neck squamous-cell carcinomas
121. Microvessel count and cerebrospinal fluid basic fibroblast growth factor in children with brain tumors
122. Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis
123. Enhancement of tumor growth and vascular density by transfection of vascular endothelial growth factor into MCF-7 human breast carcinoma cells
124. Expression of vascular endothelial growth factor does not promote transformation but confers a growth advantage in vivo to Chinese hamster ovary cells
125. In vitro neutralization of vascular endothelial growth factor activation of Flk-1 by a monoclonal antibody
126. Inhibition of vascular endothelial growth factor induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies from a phage display library
127. Inhibition of vascular endothelial growth factor induced mitogenesis of human endothelial cells by a chimeric anti-KDR receptor antibody
128. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors
129. Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence
130. Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/Flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo
131. Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells
132. Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor
133. Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors
134. Angiozyme: A novel angiogenesis inhibitor
135. Flk-1 as a target for tumor growth inhibition
136. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types
137. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors
138. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model
139. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration
140. Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors
141. ZD4190: An orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy
142. Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis
143. Expression of vascular endothelial growth factor receptors in human prostate cancer
144. Vascular endothelial growth factor-mediated autocrine stimulation of prostate tumor cells coincides with progression to a malignant phenotype
145. Expression of vascular endothelial growth factor and its receptors Flt and KDR in ovarian carcinoma
146. Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer
147. Co-expression of vascular endothelial growth factor and its receptor Flt-1 in malignant pleural mesothelioma
148. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma
149. Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor
150. Expression and localization of placenta growth factor and pigf receptors in human meningiomas
151. Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors
152. KDR receptor. A key marker defining hematopoietic stem cells
153. Vascular endothelial growth factor, a possible paracrine growth factors human acute myeloid leukemia
154. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration
155. Role of vascular endothelial growth factor (VEGF) and placenta-derived growth factor (PIGF) in regulating human haemopoietic cell growth
156. Inhibition of both paracrine and autocrine VEGF/VEGFR2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemia
157. Expression of vascular endothelial growth factor (VEGF) and VEGF receptor Flk-1 in benign, premalignant, and malignant prostate tissue
158. Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells
159. Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells
160. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
161. A cancer therapy resistant to resistance (news and views)
162. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis
163. Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo
164. Role of vascular endothelial growth factor in ovarian cancer: Inhibition of ascites formation by immunoneutralization
165. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody
166. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: Novel concepts of angiostatic therapy from intravital videomicroscopy
167. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders
168. Preclinical safety evaluation of RHuMabVEGF, an antiangiogenic humanized monoclonal antibody
169. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer
170. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: Pharmacologic and long-term safety data
171. An anti-human VEGF monoclonal antibody, MV833, that exhibits potent anti-tumor activity in vivo
172. Anti-tumor and anti-metastatic effects of human-vascular-endothelial-growth-factor-neutralizing antibody on human colon and gastric carcinoma xenotransplanted orthotopically into nude mice
173. Wide spectrum of antitumor activity of a neutralizing monoclonal antibody to human vascular endothelial growth factor
174. Suppression of ascites formation and re-accumulation associated with human ovarian cancer by an anti-VPF monoclonal antibody in vivo
175. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice
176. A strategy for antitumor vascular therapy by targeting the vascular endothelial growth factor: Receptor complex
177. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis
178. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis
179. Overexpression of vascular endothelial growth factor C is related to lymphogenous metastasis in early gastric carcinoma
180. Localization of vascular endothelial growth factor-D in malignant melanoma suggests a role in tumour angiogenesis
181. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics
182. Lymphangiogenesis and tumor metastasis: Myth or reality
183. Monoclonal antibodies to vascular endothelial growth factor-D block Its Interactions with both VEGF receptor-2 and VEGF receptor-3
184. Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ
185. An antagonistic vascular endothelial growth factor (VEGF) variant inhibits VEGF-stimulated receptor autophosphorylation and proliferation of human endothelial cells
186. Monoclonal antibodies targeting the VEGF receptor-2 (Flk-1/KDR) as an anti-angiogenic therapeutic strategy
187. Vascular endothelial growth factor as a marker of tumor endothelium
188. Monoclonal antibody strategies to block angiogenesis
189. The vascular endothelial growth factor receptor KDR/Flk-1 is a major regulator of malignant ascites formation in the mouse hepatocellular carcinoma model
190. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases
191. Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel
192. Effects of an antibody to vascular endothelial growth factor receptor-2 on survival, tumor vascularity, and apoptosis in a murine model of colon carcinomatosis
193. Preovulatory treatment of mice with anti-VEGF receptor 2 antibody inhibits angiogenesis in corpora lutea
194. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts
195. 'Accidental' anti-angiogenic drugs: Anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples
196. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
197. Vascular Endothelial Growth Factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro
198. Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cells
199. Complete inhibition of VEGF activities with a bifunctional diabody directed against both VEGF receptors, Flt-1 and KDR
200. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development
201. Expression of the avian VEGF receptor homologues quek1 and quek2 in blood-vascular and lymphatic endothelial and non-endothelial cells during quail embryonic development
202. Involvement of vascular endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell lining during tumor angiogenesis
203. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth
204. Inhibition of tumor angiogenesis by synthetic receptor tyrosine kinase inhibitors
205. Targeting Vascular Endothelial Growth Factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors
206. Angiogenesis: New targets for the development of anticancer chemptherapies
207. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis
208. Inhibition of angiogenesis by blocking activation of the vascular endothelial growth factor receptor 2 leads to decreased growth of neurogenic sarcomas
209. The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts
210. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent
211. Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms
212. New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis
213. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain
214. Bioactivity of anti-angiogenic ribozymes targeting Flt-1 and KDR Mrna
215. Pharmacokinetics of an antiangiogenic ribozyme (angiozyme) in the mouse
216. Acute toxicology and pharmacokinetic assessment of a ribozyme (angiozyme) targeting vascular endothelial growth factor receptor mrna in the Cynomolgus monkey
217. Pharmacokinetics and tolerability of an antiangiogenic ribozyme (angiozyme) in healthy volunteers
218. Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cells
219. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastasis disease
220. Comparison of several antiangiogenic regimens alone and with cytotoxic therapies in the Lewis lung carcinoma